Another notable valuation metric for PBH is its P/B ratio of 2.28. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total ...

PBH currently has a forward P/E ratio of 17.73, while SYK has a forward P/E of 28.63. We also note that PBH has a PEG ratio of 2.53. This popular figure is similar to the widely-used P/E ratio, ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our Multi-Factor Investor model based on the published strategy of ...

Clinical investigators’ (CIs) practice patterns for patients with hormone receptor-positive metastatic breast cancer (HR+ mBC) harboring PI3K/AKT/PTEN pathway abnormalities (PAPm). Hope S. Rugo , ...

When a caller asked about Stryker Corporation (NYSE:SYK), Cramer replied: “I like Stryker, but you know, I don’t like it enough. I don’t like it as much as if it was Intuitive Surgical.

Novartis published trial results showing its drug succeeded in tackling difficult to treat breast cancer with PIK3CA mutation, after other pharma giants including Roche failed and abandoned ...

Additionally, it has also been evaluated in combination with sacituzumab govitecan in a phase I study, demonstrating favorable tolerability. 46,47 Prexasertib, a CHK1 inhibitor, showed limited ...